SpecimenSeq™ BMMCs & PBMCs

SpecimenSeq™ AML
BMMCs and PBMCs

The SpecimenSeq™ BMMCs and PBMCs inventory report contains:

  • 536 detections of 35 specific genes
  • 22 unique AML patients
  • 16 of the patient cases also include matched BMMCs + PBMCs
 

Inventory Request Submission:

  1. Download and review the inventory report.
  2. Highlight your samples of interest and save the report.
  3. Submit the saved inventory report file via the contact form linked below, along with any additional details or requests.

Conduct Smarter Oncology R&D Faster With SpecimenSeq™

Overview:

Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. SpecimenSeq makes this challenge easier for hematological oncology developers by delivering access to fully consented, ethically collected BMMCs and PBMCs characterized with the Illumina TruSight Myeloid Panel.

Image

SpecimenSeq™

Deliverables &
Characterization

AML BMMCs and PBMCs

BMMCs, PBMCs, and BMMCs + PBMCs Matched Sets

Biospecimen FormatCharacterization reports
BMMCS• Clinical information and pathology report
• Qiagen’s Clinical Insights (QCI) pipeline report
• Previous treatment information (if applicable)
• Flow Cytometry characterization (if available)
PBMCS• Clinical information and pathology report
• Qiagen’s Clinical Insights (QCI) pipeline report
• Previous treatment information (if applicable)
BMMCS + PBMCS• Clinical information and pathology report
• Qiagen’s Clinical Insights (QCI) pipeline report
• Previous treatment information (if applicable)
• Flow Cytometry characterization (if available)

NGS Characterization

TRUSIGHT MYELOID SEQUENCING PANEL GENE LIST
ABL1CEBPAHRASMYD88SF3B1
AKT1CSF3RIDH1NOTCH1SMC1A
ATRXCUX1IDH2NPM1SMC3
BCORDNMT3AIKZF1NRASSRSF2
BCORL1ETV6/TELJAK2GPDGFRASTAG2
BRAFEZH2JAK3PHF6TET2
CALRFBXW7KDM6APTENTP53
CBLFLT3KITPTPN11U2AF1
CBLBGATA1KRASRAD21WT1
CBLCGATA2MLLRUNx1ZRSR2
CDKN2AGNASMPLSETBP1 

NGS results are delivered via a Qiagen Clinical Insights (QCI) report that includes:

  • Genomic variants that have been shown to have clinical relevance
  • Pathogenicity and level of clinical significance according to clinical guidelines
  • Predicted protein changes
  • Relevant drug treatments or resistance to drugs based on the genetic variants
  • Relevant active clinical trials for patients that would harbor the same genomic variants as were identified in the biospecimen sample

Additional characteristics are available through our expert, integrated service laboratories.

Image

IHC Services

Image

Cell Services

Applications:

Image

Biomarker
Discovery

Verification of the presence of biomarker targets in your populations of interest

Image

Assessing
Mutations

Confirmation of driver mutations and other clinically relevant genomic variants in viable BMMCs and PBMCs

Image

Oncology
Therapeutics

Acceleration of timelines for identifying responders versus non-responders and efficacy evaluations for new cancer therapies

To propel your projects with The Power of Discovery.™

Contact Us Today

Let us know about your project!

Image